Adam Feuerstein

TheStreet Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 480
Article

BIO CEO Conference Live Blog

By Adam Feuerstein

Follow all the biotech news and social media conversation from the 2012 BIO CEO & Investor Conference.

07:27AM 02/13/12

Article

Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

07:28AM 02/10/12

Article

6 Drug Stocks Unworthy of Biotech Bull Market

By Adam Feuerstein

The biotech sector is having a party but not all stocks deserve invites. Here's a list of over-valued or undeserving biotech stocks.

04:37PM 02/07/12

Article

FDA Skeptical of Amgen Drug Ahead of Panel

By Adam Feuerstein

Amgen's efforts to expand use of its new drug Xgeva met with some resistance from an FDA review posted Monday.

09:13AM 02/06/12

Article

Idenix Falls Casualty to Gilead Hep C Hoopla

By Adam Feuerstein

Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.

11:13AM 02/03/12

Article

Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance

By Adam Feuerstein

The star of Gilead's fourth-quarter call was its Hep C drug GS-7977, helping investor overlook lower-than-expected 2012 guidance.

07:48AM 02/03/12

Article

Medivation's Prostate Cancer Drug: Survival Benefit With Low Seizure Risk

By Adam Feuerstein

Medivation's MDV3100 significantly prolonged survival in prostate cancer patients and seizures -- an investor concern -- doesn't appear to be a problem.

06:05PM 01/31/12

Article

Vertex Wins Early Approval of Cystic Fibrosis Drug

By Adam Feuerstein

Vertex's Kalydeco is the first therapy to treat an underlying genetic cause of cystic fibrosis.

01:39PM 01/31/12

Article

Biogen's 2012 Forecast Disappoints

By Adam Feuerstein

Biogen guided to lower-than-expected earnings for 2012.

07:26AM 01/31/12

Article

Vertex Hep C Sales Growth Nears End

By Adam Feuerstein

Fourth-quarter sales of Vertex's Incivek may hit a high-water mark that will not be equaled as sales level off in 2012.

06:33AM 01/31/12

« Back
Page 1 of 480

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
Dow Jones S&P 500 NASDAQ 10-Year Note
12,801.23 1,342.64 2,903.88 20.00
Oil *
118.15
DOWN
89.23
DOWN
9.31
DOWN
23.35
UP
0.31
10 Yr
2.00%
SPDR Gold
167.14
-0.69%
-0.69%
-0.80%
+1.57%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet